Authors: Nyandoto, P Muhonen, T Hakala, T Dombrowski, MP Joensuu, H

Citation: P. Nyandoto et al., Financial compensation for radiotherapy-related adverse events in a judicial system where proof of medical negligence is not required, INT J RAD O, 51(1), 2001, pp. 209-212

Authors: Hernberg, M Pyrhonen, S Muhonen, T

Citation: M. Hernberg et al., Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials, J IMMUNOTH, 22(2), 1999, pp. 145-154

Authors: Ilmonen, S Kariniemi, AL Vlaykova, T Muhonen, T Pyrhonen, S Asko-Seljavaara, S

Citation: S. Ilmonen et al., Prognostic value of tumour vascularity in primary melanoma, MELANOMA RE, 9(3), 1999, pp. 273-278

Authors: Vlaykova, T Laurila, P Muhonen, T Hahka-Kemppinen, M Jekunen, A Alitalo, K Pyrhonen, S

Citation: T. Vlaykova et al., Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression, MELANOMA RE, 9(1), 1999, pp. 59-68

Authors: Pajari, H Koskimies, O Muhonen, T Kaariainen, H

Citation: H. Pajari et al., The burden of genetic disease and attitudes towards gene testing in Alportsyndrome, PED NEPHROL, 13(6), 1999, pp. 471-476

Authors: Vlaykova, T Talve, L Hahka-Kemppinen, M Hernberg, M Muhonen, T Franssila, K Collan, Y Pyrhonen, S

Citation: T. Vlaykova et al., MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma, ONCOL-BASEL, 57(3), 1999, pp. 242-252